Elevance (ELV) Q3 2024 Earnings Transcript

Elevance Health cut 2024 adjusted diluted EPS guidance to about $33 from prior expectations after third-quarter adjusted EPS came in at $8.37, hit by Medicaid medical costs running at 3x to 5x historical averages and a consolidated benefit expense ratio of 89.5% (+270 bps y/y). Revenue rose 5%+ to $44.7 billion and commercial membership grew nearly 600,000, but Medicaid margins remain pressured into 2025 as rate resets lag acuity. Management reiterated long-term EPS growth of at least 12% annually and highlighted growth in Carelon, ACA expansion, and AI-driven efficiency initiatives.

Analysis

The key read-through is that ELV’s miss is not a one-quarter noise event; it is a pricing lag problem with asymmetric earnings exposure to Medicaid that can persist into 2025. The market should treat this as a near-term denominator reset: management has effectively admitted the earnings bridge back to prior growth is now contingent on state rate updates catching up to member acuity, which is usually a multi-quarter process. That matters because the company’s credibility on long-duration EPS compounding is intact, but the path to that compounding is now visibly flatter, which can compress the multiple even if the long-term thesis survives.

Second-order beneficiaries are the more diversified managed care names and service vendors with less Medicaid mix, because ELV’s pressure reinforces a classic investor preference for cleaner earnings streams over operating leverage to state reimbursement. In particular, any payer with lighter government exposure or better commercial mix should screen better in a tape where the street will likely cut ELV’s 2025 EPS model and defer the recovery. The Carelon growth narrative helps, but it may not be enough to offset the fact that the core underwriting engine is temporarily operating below normalized economics.

The contrarian point is that this may be a better long-term entry than the headline suggests if you believe the rate reset is real and not a structural deterioration in the book. Management is signaling that the margin damage is mostly timing, not permanent unit economics; if that proves true, the market will be forced to re-rate ELV once state updates begin to reflect the new acuity baseline. The main catalyst to watch over the next 1-2 quarters is whether 2025 draft rates show meaningful catch-up; if they do not, the stock likely remains range-bound as investors price in a longer earnings drought.

Key Decisions for Investors

• Avoid initiating new long exposure to ELV ahead of 2025 guidance; wait for confirmation that January and midyear Medicaid rates are re-basing to acuity, likely a 1-2 quarter process. Risk/reward is poor until the street stops cutting forward EPS.
• Use any post-earnings bounce to short ELV vs. UNH or HUM as a relative-value hedge: ELV has the cleanest near-term downside to consensus revisions because Medicaid is the dominant moving piece, while peers with lower state-rate sensitivity should de-rate less.
• For investors who want to own the eventual recovery, consider a phased long ELV strategy only after evidence of rate catch-up in early 2025; the setup is attractive for 12-18 months out if the issue is truly timing, but the next 60-90 days are likely headline-driven and choppy.
• Buy downside protection on ELV through put spreads into the next guidance cycle if already long the name; the earnings reset risk is not fully resolved and another cut to 2025 assumptions would likely trigger a fresh de-rating.
• Favor overweights in managed care names with less Medicaid underwriting risk and more visible commercial pricing power over the next quarter; ELV’s read-through should widen the performance gap toward cleaner earnings compounds.